デフォルト表紙
市場調査レポート
商品コード
1086075

自閉スペクトラム症 (ASD) 治療薬の市場規模・シェア・展望・機会 (2022年~2028年):薬剤タイプ・年齢層・流通チャネル・地域別

Autism Spectrum Disorder Therapeutics Market, by Drug Type, by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 308 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
自閉スペクトラム症 (ASD) 治療薬の市場規模・シェア・展望・機会 (2022年~2028年):薬剤タイプ・年齢層・流通チャネル・地域別
出版日: 2022年05月19日
発行: Coherent Market Insights
ページ情報: 英文 308 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

自閉スペクトラム症 (ASD) の有病率の世界的な増加が自閉スペクトラム症 (ASD) 治療薬市場の成長を後押しすると予想されています。一方で、医薬品の承認と販売に関する厳しい規制、継続的な監視が同市場の成長の潜在的な障壁となる見通しです。

当レポートでは、世界の自閉スペクトラム症 (ASD) 治療薬の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制・償還シナリオ、パイプラインの分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・法規制・動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な発展
  • 規制状況
  • 提携・協力
  • 疫学分析
  • パイプライン分析・承認製品の分析
  • 規制シナリオ
  • 償還シナリオ
  • ポーターのファイブフォース分析

第4章 世界の自閉スペクトラム症 (ASD) 治療薬市場:薬剤タイプ別

  • アリピプラゾール
  • リスペリドン
  • メラトニン
  • CM-AT
  • ブメタニド
  • バロバプタン

第5章 世界の自閉スペクトラム症 (ASD) 治療薬市場:年齢層別

  • 幼児
  • 成人

第6章 世界の自閉スペクトラム症 (ASD) 治療薬市場:流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 世界の自閉スペクトラム症 (ASD) 治療薬市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • アフリカ
  • 中東

第8章 競合情勢

  • 企業プロファイル
    • F. Hoffmann-La Roche AG
    • Neurim Pharmaceuticals, Inc.
    • Yamo Pharmaceuticals LLC
    • Servier Laboratories Ltd.
    • Otsuka Holdings Co. Ltd.
    • Curemark LLC
    • Oryzon Genomics SA
    • GW Pharmaceuticals Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Zynerba Pharmaceuticals Inc.
    • STALICLA SA
    • Novartis AG
    • Pfizer, Inc.
    • Bristol Myers Squibb
  • アナリストの見解

第9章 セクション

目次
Product Code: CMI2643

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

Global Autism Spectrum Disorder Therapeutics Market, By Age Group:

Child

Adult

Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Autism Spectrum Disorder Therapeutics Market, By Region:

North America

By Country:

U.S.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Canada

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Germany

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Italy

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Spain

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

France

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Russia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Europe

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

China

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Japan

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

India

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

ASEAN

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Australia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

South Korea

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Asia Pacific

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Mexico

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Argentina

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Latin America

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Israel

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Middle East

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country/Region:

South Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Central Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

F. Hoffmann-La Roche AG.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Neurim Pharmaceuticals, Inc.

Yamo Pharmaceuticals LLC

Servier Laboratories Ltd.

Otsuka Holdings Co. Ltd.

Curemark LLC

Oryzon Genomics S.A.

GW Pharmaceuticals Plc.

Teva Pharmaceutical Industries Ltd.

Zynerba Pharmaceuticals Inc.

Stalicla SA.

Novartis AG

Pfizer, Inc.

Bristol Myers Squibb.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Age Group
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Collaborations & Partnerships
  • Epidemiology Analysis
  • Pipeline Analysis & Approved Product Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Porter's Five Forces model

4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Aripiprazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Risperidone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Melatonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • CM-AT
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Bumetanide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Balovaptan
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Child
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Neurim Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Yamo Pharmaceuticals LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Servier Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Otsuka Holdings Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Curemark LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Oryzon Genomics S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GW Pharmaceuticals Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zynerba Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • STALICLA SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact